RecruitingNCT07155252

Home-based Oral Glucose Tolerance Test for Type 1 Diabetes Screening


Sponsor

Yale University

Enrollment

60 participants

Start Date

Aug 26, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims at quantifying the accuracy of a self-administered fingerstick based glucose tolerance test (GTT@Home) respect to the gold-standard in-clinic venous plasma measures during the oral glucose tolerance test (OGTT) across a wide range of glycemic values in people at risk for clinical type 1 diabetes (T1D) (carriers of at least one islet autoantibody) or with new onset Stage 3 T1D within 100 days from the diagnosis.


Eligibility

Min Age: 8 YearsMax Age: 45 Years

Inclusion Criteria7

  • Body weight ≥43 kg
  • Presence of at least one islet autoantibody and/or≥ diagnosis of clinical T1D within 100 days.
  • Documentation of the presence at least 1 islet autoantibody
  • If participants meet ADA diagnostic criteria for Stage 3 type 1 diabetes, they will be eligible if the enrollment occurs within 100 days from the diagnosis and are at least 12 years old.
  • Participants must be in good general health without other acute (e.g. infectious disease) febrile or chronic illnesses (e.g. uncontrolled asthma requiring high steroid doses, chronic arthritis) that in the judgment of the investigator could jeopardize participant safety or interfere with the study,
  • Ability to give consent/assent
  • Able to understand written and spoken English

Exclusion Criteria3

  • Currently pregnant or becomes pregnant during the study
  • Participants on sodium glucose cotransporter inhibitors (SGLTi).
  • Donated blood in the past 8 weeks.

Interventions

DIAGNOSTIC_TESTGTT@Home

self-administered fingerstick based glucose tolerance test


Locations(1)

Yale University Pediatric and Adult Diabetes Clinic

New Haven, Connecticut, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07155252


Related Trials